Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1990 Feb;53(2):96–101. doi: 10.1136/jnnp.53.2.96

Subcutaneous apomorphine in the treatment of Parkinson's disease.

J P Frankel 1, A J Lees 1, P A Kempster 1, G M Stern 1
PMCID: PMC487943  PMID: 2313313

Abstract

Apomorphine a dopamine receptor agonist was given subcutaneously to 57 levodopa treated parkinsonian patients with refractory off-period disabilities for a median period of 16 months. In 30 given intermittent suprathreshold injections the mean number of hours spent in a disabling off state fell from 6.9 to 2.9. Similar benefit was observed in 21 patients receiving continuous infusions with additional boluses on demand by mini-pump (mean reduction of hours off from 9.9 to 4.5). Twelve patients have been treated for over two years without tachyphylaxis or loss of response. The incidence of neuropsychiatric side-effects has been low (7%). Six patients failed to show a sustained worthwhile response; severe disabilities during "on" periods being the major problem. Subcutaneous apomorphine is proposed as an effective treatment for patients with incapacitating "off" period disabilities refractory to oral medication and should be considered before experimental implantation procedures.

Full text

PDF
96

Images in this article

96Image
on p.96
97Image
on p.97

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Agid Y., Pollak P., Bonnet A. M., Signoret J. L., Lhermitte F. Bromocriptine associated with a peripheral dopamine blocking agent in treatment of Parkinson's disease. Lancet. 1979 Mar 17;1(8116):570–572. doi: 10.1016/s0140-6736(79)91003-1. [DOI] [PubMed] [Google Scholar]
  2. Birkmayer W., Riederer P., Ambrozi L., Youdim M. B. Implications of combined treatment with 'Madopar' and L-deprenil in Parkinson's disease. A long-term study. Lancet. 1977 Feb 26;1(8009):439–443. doi: 10.1016/s0140-6736(77)91940-7. [DOI] [PubMed] [Google Scholar]
  3. Bunney B. S., Aghajanian G. K., Roth R. H. Comparison of effects of L-dopa, amphetamine and apomorphine on firing rate of rat dopaminergic neurones. Nat New Biol. 1973 Sep 26;245(143):123–125. doi: 10.1038/newbio245123a0. [DOI] [PubMed] [Google Scholar]
  4. Chaudhuri K. R., Critchley P., Abbott R. J., Pye I. F., Millac P. A. Subcutaneous apomorphine for on-off oscillations in Parkinson's disease. Lancet. 1988 Nov 26;2(8622):1260–1260. doi: 10.1016/s0140-6736(88)90860-4. [DOI] [PubMed] [Google Scholar]
  5. Christmas T. J., Kempster P. A., Chapple C. R., Frankel J. P., Lees A. J., Stern G. M., Milroy E. J. Role of subcutaneous apomorphine in parkinsonian voiding dysfunction. Lancet. 1988 Dec 24;2(8626-8627):1451–1453. doi: 10.1016/s0140-6736(88)90932-4. [DOI] [PubMed] [Google Scholar]
  6. Corsini G. U., Del Zompo M., Gessa G. L., Mangoni A. Therapeutic efficacy of apomorphine combined with an extracerebral inhibitor of dopamine receptors in Parkinson's disease. Lancet. 1979 May 5;1(8123):954–956. doi: 10.1016/s0140-6736(79)91725-2. [DOI] [PubMed] [Google Scholar]
  7. Corsini G. U., Pitzalis G. F., Bernardi F., Bocchetta A., Del Zompo M. The use of dopamine agonists in the treatment of schizophrenia. Neuropharmacology. 1981 Dec;20(12B):1309–1313. [PubMed] [Google Scholar]
  8. Düby S. E., Cotzias G. C., Papavasiliou P. S., Lawrence W. H. Injected apomorphine and orally administered levodopa in Parkinsonism. Arch Neurol. 1972 Dec;27(6):474–480. doi: 10.1001/archneur.1972.00490180010004. [DOI] [PubMed] [Google Scholar]
  9. Hardie R. J., Lees A. J., Stern G. M. On-off fluctuations in Parkinson's disease. A clinical and neuropharmacological study. Brain. 1984 Jun;107(Pt 2):487–506. doi: 10.1093/brain/107.2.487. [DOI] [PubMed] [Google Scholar]
  10. Hoehn M. M., Elton R. L. Low dosages of bromocriptine added to levodopa in Parkinson's disease. Neurology. 1985 Feb;35(2):199–206. doi: 10.1212/wnl.35.2.199. [DOI] [PubMed] [Google Scholar]
  11. Kempster P. A., Lees A. J., Crichton P., Frankel J. P., Shorvon P. Off-period belching due to a reversible disturbance of oesophageal motility in Parkinson's disease and its treatment with apomorphine. Mov Disord. 1989;4(1):47–52. doi: 10.1002/mds.870040108. [DOI] [PubMed] [Google Scholar]
  12. Lees A. J., Shaw K. M., Kohout L. J., Stern G. M., Elsworth J. D., Sandler M., Youdim M. B. Deprenyl in Parkinson's disease. Lancet. 1977 Oct 15;2(8042):791–795. doi: 10.1016/s0140-6736(77)90725-5. [DOI] [PubMed] [Google Scholar]
  13. Linström F. D., Liedén G., Enström M. S. Dose-related levodopa-induced haemolytic anaemia. Ann Intern Med. 1977 Mar;86(3):298–300. doi: 10.7326/0003-4819-86-3-298. [DOI] [PubMed] [Google Scholar]
  14. Mathers S. E., Kempster P. A., Law P. J., Frankel J. P., Bartram C. I., Lees A. J., Stern G. M., Swash M. Anal sphincter dysfunction in Parkinson's disease. Arch Neurol. 1989 Oct;46(10):1061–1064. doi: 10.1001/archneur.1989.00520460037010. [DOI] [PubMed] [Google Scholar]
  15. Mendez M. F., Geehan G. R., Jr Cortical auditory disorders: clinical and psychoacoustic features. J Neurol Neurosurg Psychiatry. 1988 Jan;51(1):1–9. doi: 10.1136/jnnp.51.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Nutt J. G., Woodward W. R., Carter J. H. Clinical and biochemical studies with controlled-release levodopa/carbidopa. Neurology. 1986 Sep;36(9):1206–1211. doi: 10.1212/wnl.36.9.1206. [DOI] [PubMed] [Google Scholar]
  17. Pezzoli G., Tesei S., Ferrante C., Cossutta E., Zecchinelli A., Scarlato G. Madopar HBS in fluctuating parkinsonian patients: two-year treatment. Mov Disord. 1988;3(1):37–45. doi: 10.1002/mds.870030106. [DOI] [PubMed] [Google Scholar]
  18. Poewe W., Kleedorfer B., Gerstenbrand F., Oertel W. Subcutaneous apomorphine in Parkinson's disease. Lancet. 1988 Apr 23;1(8591):943–943. doi: 10.1016/s0140-6736(88)91755-2. [DOI] [PubMed] [Google Scholar]
  19. Pollak P., Champay A. S., Hommel M., Perret J. E., Benabid A. L. Subcutaneous apomorphine in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1989 Apr;52(4):544–544. doi: 10.1136/jnnp.52.4.544. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Stibe C. M., Lees A. J., Kempster P. A., Stern G. M. Subcutaneous apomorphine in parkinsonian on-off oscillations. Lancet. 1988 Feb 20;1(8582):403–406. doi: 10.1016/s0140-6736(88)91193-2. [DOI] [PubMed] [Google Scholar]
  21. Territo M. C., Peters R. W., Tanaka K. R. Autoimmune hemolytic anemia due to levodopa therapy. JAMA. 1973 Dec 10;226(11):1347–1348. [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES